Canadian radiopharmaceutical developer Draxis Health today reported a series of senior level organization changes it said are designed to further streamline the leadership of its organization. The notice comes on the heels of an announcement yesterday that the Mississauga, Ontario-based firm had estimated diluted net earnings for its fiscal 2007 second quarter (end-June 30) of approximately $.04 (U.S.) per share.
Effective immediately, Jean-Pierre Robert assumes the role of president of Draxis Specialty Pharmaceuticals (DSP), the company's wholly owned operating subsidiary that provides products in three categories; sterile products, non-sterile products and radiopharmaceutical products. Previously Robert was president of DraxImage, the division of DSP that produces and markets its own radiopharmaceutical products.
John Durham, currently president of Draxis Pharma, will resign, effective today, to pursue other interests, the company stated.
Robert will now also have responsibility for Draxis Pharma, the contract manufacturing division of DSP, which produces sterile and non-sterile products for clients in the pharmaceutical and biotechnology sectors. Reporting to Robert will be the three business units of DSP together with their shared services and support systems.